Wall Street Zen Upgrades OnKure Therapeutics (NASDAQ:OKUR) to Sell

OnKure Therapeutics (NASDAQ:OKUR) was upgraded by stock analysts at Wall Street Zen to a “sell” rating in a note issued to investors on Saturday.

Several other analysts have also issued reports on OKUR. HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of OnKure Therapeutics in a report on Tuesday, August 26th. Zacks Research lowered OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of OnKure Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, OnKure Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $32.33.

OnKure Therapeutics Trading Up 1.2%

Shares of NASDAQ:OKUR opened at $3.39 on Friday. OnKure Therapeutics has a 1 year low of $1.70 and a 1 year high of $17.76. The business has a fifty day simple moving average of $2.81 and a 200 day simple moving average of $2.57. The firm has a market cap of $45.87 million, a price-to-earnings ratio of -0.71 and a beta of 0.43.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.09. On average, sell-side analysts forecast that OnKure Therapeutics will post -4.05 EPS for the current year.

Hedge Funds Weigh In On OnKure Therapeutics

Several institutional investors have recently bought and sold shares of the stock. ADAR1 Capital Management LLC bought a new position in OnKure Therapeutics during the first quarter valued at about $43,000. XTX Topco Ltd acquired a new stake in shares of OnKure Therapeutics in the second quarter valued at about $25,000. Bailard Inc. acquired a new stake in shares of OnKure Therapeutics in the second quarter valued at about $34,000. Rangeley Capital LLC acquired a new stake in shares of OnKure Therapeutics in the second quarter valued at about $71,000. Finally, Highbridge Capital Management LLC grew its position in shares of OnKure Therapeutics by 51.2% in the second quarter. Highbridge Capital Management LLC now owns 663,607 shares of the company’s stock valued at $1,586,000 after purchasing an additional 224,810 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.